CERVICAL LENGTH SCREENING FOR PREMATURITY PREVENTION

VALERIE RAPPAPORT MD
DIRECTOR, PRENATAL DIAGNOSIS AND GENETICS
UNIVERSITY OF NEW MEXICO, DEPT OB/GYN
MAY 8, 2015


NORMAL CERVICAL LENGTH

Cervical length is normally distributed and remains relatively constant until the third trimester.

Heath found at 23 weeks a mean length of 38 mm.

lams found a mean length at 24 weeks of 35 mm and at 28 weeks of 34 mm.

DELIVERY BEFORE 35 WEEKS ACCORDING TO CERVICAL LENGTH MEASURED BY TRANSVAGINAL ULTRASONOGRAPHY AT 24 WEEKS' GESTATION



lams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. N Engl J Med1996;334:569

ACOG 2001

- Although transvaginal ultrasound screening of cervical length can predict increased risk of preterm birth, there is no evidence that this information can be used to improve outcomes. Consultation and the proposed location of birth should be considered.
- Other management options, such as cerclage, activity restriction, tocolytics, and prophylactic steroids await appropriate evaluation by randomized trials.

2012

Progesterone and preterm birth prevention: translating clinical trials data into clinical practice

Society for Maternal-Fetal Medicine Publications
Committee, with the assistance of Vincenzo Berghella, MD

American Journal of Obstetrics & Gynecology MAY 2012

PROGESTERONE AND PRETERM BIRTH PREVENTION: TRANSLATING CLINICAL TRIALS DATA INTO CLINICAL PRACTICE

SOCIETY FOR MATERNAL-FETAL MEDICINE PUBLICATIONS COMMITTEE, WITH THE ASSISTANCE OF VINCENZO BERGHELLA, MD

OBJECTIVE: We sought to provide evidence-based guidelines for using progestogens for the prevention of preterm birth (PTB).

RESULTS AND RECOMMENDATIONS:

In singleton gestations with prior PTB 20-36 6/7 weeks, 17-alpha-hydroxy-progesterone caproate 250 mg intramuscularly weekly, preferably starting at 16-20 weeks until 36 weeks, is recommended.

In these women with prior PTB, if the transvaginal ultrasound CL shortens to 25mm at 24 weeks, cervical cerclage may be offered.

PROGESTERONE AND PRETERM BIRTH PREVENTION: TRANSLATING CLINICAL TRIALS DATA INTO CLINICAL PRACTICE

SOCIETY FOR MATERNAL-FETAL MEDICINE PUBLICATIONS COMMITTEE, WITH THE ASSISTANCE OF VINCENZO BERGHELLA, MD

OBJECTIVE: We sought to provide evidence-based guidelines for using progestogens for the prevention of preterm birth (PTB).

RESULTS AND RECOMMENDATIONS:

Summary of randomized studies indicates that in women with singleton gestations, no prior PTB, and short CL 20mm at 24 weeks, vaginal progesterone, either 90-mg gel or 200-mg suppository, is associated with reduction in PTB and perinatal morbidity and mortality, and can be offered in these cases.

VAGINAL PROGESTERONE FOR LOW RISK WOMEN WITH SHORT TV CL

- 250 women, 90% were singleton pregnancies, 85% had no prior PTB
 - TV CL <1.5cm at 20-25 weeks</p>
 - Nightly vaginal progesterone 200mg
 - 19% vs 34% PTB less than 34 weeks
 - Benefit was especially great in women without a prior preterm birth
 - The prevalence of TV CL < 1.5mm was 1.7%</p>

 Fonseca et al, Progesterone and the risk of Preterm Birth among women with a short cervix, NEJM 2007:357:462-9 Level 1

SCREENING EFFICACY

- The number of women screened to prevent one preterm birth is 387
- If you identify a women with CL 1.5 or less, the number needed to treat to prevent one PTB below 34 weeks if about 7 women.

VAGINAL PROGESTERONE GEL 90MG

- 458 women, singleton pregnancy
 - TV CL 1.0 2.0mm at 19-236/7 weeks
 - Vaginal progesterone gel 90mg daily at 20- 23 6;7 weeks until 36 6/7 weeks
 - 45% reduction in preterm birth before 33 weeks
 - 9% vs 16% (without prior PTB 8% vs 15%)
 - Incidence of preterm birth before 28 weeks and before 35 weeks as well as respiratory distress syndrome was also reduced.

 Hassan et, Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix, Ultrasound Obstet Gyneol 2011:38:18-31 Level 1

SCREENING EFFICACY

- Prevalence of cervical length 10- 20 mm in this study was 2.3%
- The number of women needed to be screened to prevent one preterm birth less than 33 weeks is 604
- If a short cervical length is detected, the number needed to treat to prevent one preterm birth is 14

METAANALYSIS

- 554 singleton, no prior PTB
 - TV CL less than 2.5 and mostly less than 25 weeks
 - Vaginal progesterone nightly
 - Significant reduction in preterm birth less than 33 weeks
 - Reduction in neonatal morbidity and mortality
 - Romero et al, Vaginal progesterone in women with an asymptomatic sonographic short cervix in the mid trimester decreased preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data, Am J Obstet Gynecol 2012: 206:124 e 1-19 Level1

Universal screening strategy with a single TV CL at 18- 24 weeks and treatment with vaginal progesterone if the CL is 1.5cm of less is projected to result in over \$12 million saved, 22 neonatal deaths or long term sequelae prevented for every 100,000 women screened.

Readjusting for cervical length between 1.6 and 2.5 does not change these conclusions.

COST ESTIMATES FOR SINGLETON INTRAUTERINE PREGNANCY SCREENING AND TREATMENT

TABLE 2

Utility and cost estimates for patients with a singleton intrauterine pregnancy who were screened and treated to reduce preterm birth risk

Variable	Point estimate (range)	Reference	Level of evidence
Utility of neonatal death	0.01 (0.001-0.02)	34	Ш
Utility of neonatal severe morbidity	0.55 (0.50-0.60)	34,35	III
Cost of transvaginal sonogram	\$52 (\$43-74)	Local sources based on Medicaid reimbursement	Not available
Cost of vaginal progesterone (18-34 weeks)	\$283 (\$220-344)	Local sources based on Medicaid reimbursement	Not available
Cost of 17 α-hydroxyprogesterone caproate (18-34 weeks)	\$365 (\$300–440)	Local sources based on Medicaid reimbursement	Not available
Cost of neonatal severe morbidity	\$995,940 (\$200,000-1,200,000)	36	III

^{*} Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventative Task Force: a review of the process. Am J Prev Med 2001;20:(3S).

Cahill. Preterm birth prevention. Am J Obstet Gynecol 2010.

COST EFFECTIVENESS OF UNIVERSAL SCREENING VS TARGETED SCREENING

TABLE 3

Base-case cost-effectiveness analysis comparison of universal screening with the alternative strategies

Variable	Cost,\$	incremental cost, \$	Effectiveness (QALY)	Incremental effectiveness (QALY)	Average cost/ effectiveness (\$/QALY)	incremental cost/ effectiveness
Universal screening; treatment vaginal progesterone	8325	_	72.3	_	115	Dominant
High-risk screening; treatment vaginal progesterone	10,577	2252	72.0	-0.25	147	Dominated
No screening; 17-hydroxyprogesterone acetate based on medical history	9664	1339	72.1	-0.15	134	Dominated
No screening or treatment	11,560	3235	71.9	-0.36	161	Dominated

QALY, quality-adjusted life year.

Cahill. Preterm birth prevention. Am J Obstet Gynecol 2010.

PRETERM BIRTHS PREVENTED PER DOLLARS SPENT

TABLE 4

Number of preterm births at <34 weeks' gestation and cases of severe morbidity that were prevented per dollar spent by strategy, with the use of base-case estimates and an estimated annual delivery rate of 4 million in the United States

Strategy	Preterm births, n	Cases significant morbidity, n	Total cost (\$100 million)	Preterm births prevented, n	Cases significant morbidity prevented, n	Total cost saved (\$100 million)
No screening or treatment (reference)	170,920	47,810	462.4	Reference	Reference	Reference
Universal screening	75,000	34,220	333.0	95,920	13,590	129.4
High-risk screening	142,160	43,740	423.1	28,760	4070	39.3
Standard of care: 17- hydroxyprogesterone acetate	114,880	39,860	386.6	56,040	7950	79.3

Cahill. Preterm birth prevention. Am J Obstet Gynecol 2010.

UNIVERSAL SCREENING CONSIDERATIONS


- TVU CL does fulfill all of the criteria for an effective screening testing:
 - Disease is clinically important, clearly defined, natural hx. is recognizable at an early symptomatic phase
 - Screening test is safe
 - Screening technique is well described
 - Screening has reasonable, reproducible cutoffs and data
 - Results are accurate
 - Intervention is cost effective
 - Facilities for screening are readily available
 - Facilities for treatment are readily available.

WHY NOT?

- The trials have only addressed women who are already identified as having a short cervix. It is possible that a significant number of women with a short cervix may be identified without a specific universal TV screen.
- Universal screening may not produce the same results as a controlled trial.
- The available trials used different cutoffs and medications
- Appropriate equipment and trained personnel may not be available in all communities.

SMFM CONCLUSIONS

- CL screening is indicated in women with prior preterm birth
- CL screening in singleton gestations without prior PTB cannot yet be mandated universally. Nonetheless implementation of such a screening strategy should be viewed as reasonable and can be considered by individual practitioners
- Third party payers should not deny reimbursement for this screening
- Practitioners who implement universal screening should follow strict guidelines
 - TV VL needs to be performed with proper technique with quality control and monitoring
 - Clinicians should stay strictly within bounds of screening guidelines



alf TVU CL screening is performed; b17P 250 mg intramuscularly every week from 16-20 weeks to 36 weeks; ceg, daily 200-mg suppository or 90-mg gel from time of diagnosis of short CL to 36 weeks. CL, cervical length; PTB, preterm birth; 17P, 17-alpha-hydroxy-progesterone caproate; TVU, transvaginal ultrasound.


SMFM. Progesterone and preterm birth prevention. Am J Obstet Gynecol 2012.

PRIOR PTB AND SHORTENED CERVIX-IM PROGESTERONE AND CERCLAGE

- Benefits of progesterone were between 15-25mm.
- Below 15mm, no benefit of progesterone as compared to cerclage
- If the cervical length is less than 25mm
 - No treatment 34% delivered before 32 weeks
 - Cerclage 25%
 - ■17P only 21%
 - Cerclage plus 170HP 17%

PRIOR PTB, CERVICAL LENGTH SCREENING

- 5 clinical trials with 504 singleton pregnancies
 - TV CL 25mm or less at <24 weeks</p>
 - Cerclage reduced risk of PTB less than 25 weeks by 30 % and reduced neonatal morbidity by 36%
 - Screening with cervical length from 16 weeks, q
 2weeks until 23 weeks is suggested
 - Offer cerclage if 25mm or less
 - These patients should already be on progesterone however no data to say there is an additive effect for vaginal progesterone



alf TVU CL screening is performed; b17P 250 mg intramuscularly every week from 16-20 weeks to 36 weeks; ceg, daily 200-mg suppository or 90-mg gel from time of diagnosis of short CL to 36 weeks. CL, cervical length; PTB, preterm birth; 17P, 17-alpha-hydroxy-progesterone caproate; TVU, transvaginal ultrasound.


SMFM. Progesterone and preterm birth prevention. Am J Obstet Gynecol 2012.

RULES- AS WE KNOW THEM TODAY FOR SCREENING CERVICAL LENGTH

- LOW RISK POPULATION:
- Screening cervical length is performed between 18-24 weeks. No evidence of benefit of progesterone treatment outside of these ranges.
- There is no evidence that treatment with progesterone is beneficial if the cervical length is over 20mm
- Either form of vaginal progesterone can be used
- There is no evidence that IM preparations would be effective.

PROTOCOL

No Prior PTB- If a TV CL of 20mm or less is identified at less than 24 weeks, vaginal progesterone can be offered for prevention of PTB



alf TVU CL screening is performed; b17P 250 mg intramuscularly every week from 16-20 weeks to 36 weeks; ceg, daily 200-mg suppository or 90-mg gel from time of diagnosis of short CL to 36 weeks. CL, cervical length; PTB, preterm birth; 17P, 17-alpha-hydroxy-progesterone caproate; TVU, transvaginal ultrasound.

SMFM. Progesterone and preterm birth prevention. Am J Obstet Gynecol 2012.

CERCLAGE VS. PROGESTERONE

- Current evidence does not support cerclage for the incidental finding of a shortened cervix in women without a prior spontaneous preterm birth or midtrimester pregnancy loss.
- Twins cerclage for a short cervix is associated with an increased rate of preterm birth at less than 35 weeks' gestation, with an RR of 2.15 (95% CI, 1.15 – 4.01).
- Women who have undergone prior cervical cone biopsy or LEEP procedures-efficacy of cerclage for a shortened cervix has not been evaluated, leaving management speculative.

- "IF AN APPROACH OF UNIVERSAL SCREENING IS TO BE ADOPTED, THEN TV CL SCREENING NEEDS TO BE DONE WITH PROPER TECHNIQUE AND WITH QUALITY ASSURANCE TO BE EFFECTIVE"
- To ensure quality, the Perinatal Quality Foundation is setting up a program on the proper training for clinical use of TV CL measurement
- Society for Maternal-Fetal Medicine Publications Committee, with the assistance of Vincenzo Berghella, MD, Progesterone and preterm birth prevention: translating clinical trials data into clinical practice, American Journal of Obstetrics & Gynecology MAY 2012

WHAT IS THE PERINATAL QUALITY FOUNDATION?

- The Maternal Fetal Medicine Foundation (MFMF) was formed in 2005 and in turn instituted the Nuchal Translucency Quality Review (NTQR). Effective January 1, 2012 the MFMF became the Perinatal Quality Foundation (perinatalquality.org).
 - The NTQR program (ntqr.org) will not change and will be joined by other initiatives. The Examiner will continue to focus on first trimester risk assessment and the NTQR program but will also include items of interest related to new developments in obstetrical care.



Home About Us Program Information Image Criteria Contact Us

Username:
Password:

Register

https://clear.perinatalquality.org/

Login

CLEAR Component	Cost	ACOG Credit	SDMS Credit
Lectures Only	Free	None	None
Lectures & Examination	\$75	1	1
Image Review	\$75	1.5	2.0
Approval Effective Dates		2013	2013 - 2016
Total	\$150	2.5	3.0

The CLEAR program consists of the following:

Education

Lecture 1: Why Measure Cervical Length Lecture 2: How to Measure Cervical Length

Lecture 3: The CLEAR Program

Examination

Cervical Image Review and Critique

The Cervical Length Education and Review (CLEAR) program provides three lectures, and optional examination and scored cervical image review. The lectures are available at no charge. Continuing medical education is available to those who complete the examination. Documentation of completion of the CLEAR program as well as CME will be provided to those who complete the lectures, examination, and pass the image review.

To access the lectures and other aspects of the CLEAR program, create a username and password above. For further information contact the Perinatal Quality Foundation at Support@perinatalquality.org





Cervix Measurement Image Criteria

Transvaginal Image
Cervix Occupies 75% of the Image
Anterior Width = Posterior Width
Maternal Bladder Empty
Internal Os Seen
External Os Seen
Cervix Canal Visible Throughout
Caliper Placement Correct
Cervix Mobility Considered



CLEAR Program Completions: **Read Disclaimer					
CLEAR ID					
Last Name					
First Name					
Location:					
State	All States 🗸				
Town/City					
# of results per page	10 🗸	Search			

MEASUREMENT OF THE CERVIX

Funnel Cervical Length Length Record A is the **Funnel** Length. THE Cervical Length B is the CP Cervical Length C Ant Lip should = C Post Lip Berghella, Ultrasound Obstet Gynecol 1997;10:161 **Burger, Ultrasound Obstet Gynecol 1997;9:188**

AIUM GUIDELINES FOR TRANSVAGINAL PROBE CARE

The endocavitary probe should be covered with a barrier (condom or probe cover).

Users need to be aware of latex sensitivity and have non-latex barriers available.

Users should wear gloves throughout the procedure.


Care should be taken to clean hands and surfaces after the procedure.

AIUM GUIDELINES FOR TRANSVAGINAL PROBE CARE

- The probe should be cleaned with soap and water immediately after the procedure.
- High-level disinfection of the probe is required between patients. Allot the time specified on the product label for high-level disinfection.
- FDA has published a list of high level disinfectants for use in processing reusable medical devices. That list may be consulted to find agents that may be useful for probe disinfection.


CERVICAL SCREENING MEASUREMENT IMAGE CRITERIA

- Transvaginal Image
- Cervix ~ 75% of the image
- Anterior = Posterior Width
- Maternal Bladder Empty
- Internal Os Seen
- External Os Seen
- Cervical Canal Visible throughout
- Caliper Placement Correct
- Cervix Mobility Considered




CERVICAL SCREENING MEASUREMENT IMAGE CRITERIA


- Transvaginal Image
- Cervix ~ 75% of the image
- Anterior = Posterior Width
- Maternal Bladder Empty
- Internal Os Seen
- External Os Seen
- Cervical Canal Visible throughout
- Caliper Placement Correct
- Cervix Mobility Considered




CRITERIA 1- NORMAL CERVIX TRANSVAGINAL VIEW



CRITERIA 2: CERVIX OCCUPIES 75% OF THE IMAGE



CERVIX DOESN'T OCCUPY 75% OF IMAGE



CRITERIA 3: ANTERIOR WIDTH = POSTERIOR WIDTH

- The anterior cervical thickness is equal in width to the posterior cervical thickness.
- The echogenicity is similar both anterior and posterior.
- There is minimal concavity created by the transducer.

CRITERIA 3: ANTERIOR WIDTH = POSTERIOR WIDTH



ANTERIOR WIDTH # POSTERIOR WIDTH





Prominent concavity at transducer face


ANTERIOR WIDTH # POSTERIOR WIDTH



Note increased echogenicity anterior portion of cervix

CRITERIA 4: EMPTY MATERNAL BLADDER

Bladder



MATERNAL BLADDER NOT EMPTY





CRITERIA 5 & 6: INTERNAL AND EXTERNAL OS SEEN



TOO MUCH PRESSURE: NEITHER OS SEEN WELL





EXTERNAL OS NOT WELL SEEN






CERVICAL CANAL NOT ALL VISIBLE





PITFALL: UTERINE CONTRACTION



Contractions may obscure the internal os & mimic funneling

PITFALL: UTERINE CONTRACTION




CRITERIA 7: CERVICAL CANAL COMPLETELY VISIBLE THROUGHOUT



CRITERIA 8: CALIPER PLACEMENT CORRECT


Bladder




WHERE TO PUT THE CALIPERS?

- Where the anterior & posterior walls of the canal touch
- Not outer-most edge


Spend enough time to see whether a small echolucent area is stable, or is going to open up




B = FUNNEL A = CERVIX LENGTH



CALIPER PLACEMENT INCORRECT




HOW TO MEASURE A CURVED CERVIX: DON'T TRACE TO MEASURE THE CERVICAL LENGTH



Why Not?

HOW TO MEASURE THE CURVED CERVIX: USE MULTIPLE MEASUREMENTS




CRITERIA 9: CERVIX MOBILITY CONSIDERED

The Cervix is Dynamic

Examinations must take cervical changes into account

LOCAL CONTRACTION - SINGLE EXAMINATION



HOW LONG IS 3 MINUTES? LONGER THAN YOU THINK

- Suggested activities:
 - Fiddle with the ultrasound buttons, run through all the spectral colors available for the ultrasound image, turn the color and pulsed Doppler off and on a few times.
 - Sing the Star Spangled Banner- long version, all 4 verses.
 - Pop a bag of microwave popcorn- size large
 - Recite the Gettysburg address- twice
 - If kids are in the room- run through 12 verses of Old MacDonald Had a Farm
 - Do the Macarena with your left hand and foot while humming the rhythm - do not use the vag probe for percussion

DYNAMIC TECHNIQUE

Withdraw probe until blurred / Reapply


Enlarge image (2/3 of screen)

Measure Ext Os → Int Os along endo-cervical canal


Apply fundal or suprapubic pressure

Obtain 3 measurements, use shortest best Total exam time about 5 minutes

SLUDGE



AMNIOTIC FLUID (PRE-CERVICAL) SLUDGE



Kusanovic JP, Espinoza J, Romero R, et al. Clinical significance of the presence of amniotic fluid 'sludge' in asymptomatic patients at high risk for spontaneous preterm delivery. Ultrasound Obstet Gynecol 2007;30:710

CONSISTENT EXAMINATION PROTOCOLS

QUALITY OPERATOR CONSIDERATIONS

Experience w/ Transvaginal Exams

Recent Education in Standard Cervical Image Criteria

Practice in obtaining symmetrical cervical imaging (50 or more exams before proficient studies)

Documentation of Interobserver variability of 7-10% or less



Burger, Ultrasound Obstet Gynecol 1997;9:188
Berghella, Ultrasound Obstet Gynecol 1997;10:161

PRE-EXAM CONSIDERATIONS

Check the equipment

- Transducer appropriately cleaned w/ soap & water
 + soaked for sufficient time for high-level
 disinfection
- Use standard 5 to 7 MHz endovaginal probe
- Use the "EV" EndoVaginal setting (Not OB or ABD)
- Ask patient about latex sensitivity
- Empty maternal bladder
 - Void just before the exam
 - If bladder is seen to be large, stop exam & void again

TECHNIQUE

Empty maternal bladder.

Using TVU find the internal os, external os, cervical canal and endo-cervical glands.

Avoid undue pressure on the cervix.

Anterior width = Posterior width.

The cervix should occupy > 75% of the image.

Measure the closed portion of the cervix.

Perform 3 measurements over > 3 minutes.

Record the **Shortest** length that Meets Criteria.

Not the average length, and Not the prettiest picture


PRINCIPAL COMPONENTS

- Adjustment of the gain
- Image zoom,
- Put the focal zone at the cervical canal
- Use the cineloop key to adjust the image.

MEASUREMENT TECHNIQUE

- Relax probe pressure until image begins to blur, then reapply just enough pressure to create best image
- Visualize standard criteria
- Measure CL repeatedly until ▲ is < 10%
- Record the "Shortest Best Measurement"
 - Discard poor measurements Do Not Average

LOW RISK, 20 WEEKS, CL 26MM



REPORTING CONSIDERATIONS

What is "Shortest Best"?

Take repeated measurements until you get 3 that all meet criteria (anterior = posterior thickness, landmarks seen) that vary by < 10%


Of these 3 excellent images, <u>record the</u>

<u>SHORTEST one</u> – **not** the one you think is

"prettiest" – we want to minimize subjective variation

TROUBLE FINDING A GOOD IMAGE?

- Start over by relaxing pressure & finding landmarks
- Find lowermost edge of the empty bladder – internal cervical os should be directly below
- Cx axis may not lie in mid-plane of torso
- Image should fill 75% of the screen



TVU PITFALLS


Technical

Full bladder
Too much pressure
Failure to visualize entire cervical length
Incorrect caliper placement
Exam too short to visualize dynamic
cervix changes

Anatomic


Contraction Underdeveloped LUS

COMPRESSION ON ANTERIOR LIP



FOCAL MYOMETRIAL CONTRACTURE






alf TVU CL screening is performed; b17P 250 mg intramuscularly every week from 16-20 weeks to 36 weeks; ceg, daily 200-mg suppository or 90-mg gel from time of diagnosis of short CL to 36 weeks. CL, cervical length; PTB, preterm birth; 17P, 17-alpha-hydroxy-progesterone caproate; TVU, transvaginal ultrasound.

SMFM. Progesterone and preterm birth prevention. Am J Obstet Gynecol 2012.


PPTB, 18 WEEKS




SAME PATIENT AFTER 2 MIN




PRIOR PTB, 20 WEEKS, CL 19MM




POSTERIOR CX, VAGINAL WALL




ECHOGENICITY IN CERVICAL CANAL




3D IMAGING OF CERVICAL CANAL WITH IUD




LOW RISK, 19 WEEKS, CL 42MM




LOW RISK, 25 WEEKS, CL 42MM



NS 23 WEEKS, 1ST IMAGE




NS 23WK, 2ND IMAGE, 2MIN, CL 21MM



NS 3RD IMAGE, AFTER 3MIN, CL 1.5MM




NS, ON 17P, 27 WEEKS




NS 31 WEEKS, ON 17P, CL 9MM




FUNNELING?



3D IMAGING, NARROW CANAL, DISCRETE AREA OF CERVICAL LUCENCY



LOW RISK, 21 WEEKS, CL 41MM




PPTB, 21WEKS, CL 38MM, FLUID?




LOW RISK, 20 WEEKS, FUNNELING



LOWER UTERINE SEGMENT VIEW



LOW RISK, 23 WEEKS, IMAGE 1



LOW RISK, 23WKS, IMAGE 2, CL 12MM







IMAGE 3, 2 MIN, CL




LOW RISK, 20 WEEKS, CL 29 PRIOR C-SECTION




PPTB X 2, 22 WEEKS, CL 25MM




PPTB, 20 WEEKS, CERCLAGE




G1PO, 19 WEEKS, SLUDGE



G1P0, 28 WEEKS




G1PO, 24 WEEKS IMAGE 1




G1PO, 24 WEEKS, IMAGE 2, CL 10MM




NS, 20 WEEKS, IMAGE 1



NS, G3P1, 20 WEEKS



NS, 20 WEEKS, SCREENING EXAM PREVIA



SCREENING 22 WEEKS, SLUDGE

